NOIDS.wiki
Calculator
Shop Potency Calculator
Cannabis Science

Dexanabinol (HU-211): Specs, Where It Fits & Evidence

Cannabinoid · Pharmaceutical

NoPharmaceuticalSynthetic (NMDA antagonist)Trials (investigational)

Dexanabinol (HU-211) is a pharmaceutical cannabinoid, in the Synthetic (NMDA antagonist) group. A non-psychotropic synthetic that acts as an NMDA antagonist rather than a CB agonist.

Full name
Dexanabinol
Abbreviation
HU-211
Molecular formula
C25H38O3
Class / family
Synthetic (NMDA antagonist)
Precursor / from
Synthetic
Intoxicating?
No
Research status
Trials (investigational)

Where it fits

Dexanabinol (HU-211) derives from Synthetic. See the Synthetic & altered cannabinoids index for how it relates to the rest of the family.

What the research shows

Dexanabinol (HU-211) has trials (investigational)-level evidence; see the class index and related compounds for cited studies.

FAQ

Is HU-211 intoxicating? No. Dexanabinol (HU-211) is non-intoxicating.

Where does HU-211 come from? Dexanabinol (HU-211) is a wholly synthetic (3S,4S) cannabinoid enantiomer first synthesized at the Hebrew University of Jerusalem.

Why is HU-211 non-intoxicating while HU-210 is extremely potent? HU-211 is the mirror-image (3S,4S) stereoisomer of (-)-HU-210; because human CB1 receptors bind only the (3R,4R) configuration, HU-211 does not activate CB1 and instead blocks NMDA glutamate channels.

Enantiomeric Pharmacology and Traumatic Brain Injury Trials

Dexanabinol (HU-211) is the synthetic (+)-(3S,4S) enantiomer of the potent classical cannabinoid agonist HU-210, which itself is a 1,1-dimethylheptyl analogue of delta-8-THC. Because CB1 and CB2 cannabinoid receptors are strictly stereoselective for the (-)-(3R,4R) configuration, (+)-HU-211 exhibits negligible affinity for cannabinoid receptors and produces no cannabimimetic intoxication; instead, Feigenbaum et al. (1989) demonstrated that it acts as a stereospecific non-competitive antagonist of the N-methyl-D-aspartate (NMDA) glutamate receptor ion channel (PubMed PMID 2549466). In clinical development for severe traumatic brain injury (TBI), a randomized phase II study by Knoller et al. (2002) reported improved intracranial pressure control inside neurosurgical intensive care units (PubMed PMID 11912529), whereas the definitive multi-center phase III randomized controlled trial across 861 patients published by Maas et al. (2006) in The Lancet Neurology confirmed biological safety but found no statistically significant improvement in 6-month Glasgow Outcome Scale scores over placebo (PubMed PMID 16361021).

Part of the NOIDS cannabinoids index. Educational reference, not medical advice.

This article is for educational purposes only. Always follow local laws regarding cannabis preparation and use.

Scroll to Top